THE PROMISE OF NDC-1308 IN TREATING NEURODEGENERATIVE DISEASE
“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”
Dr. James Yarger, Ph.D.
NDC-1308 has a unique mechanism-of-action for inducing remyelination AND inhibiting demyelination which differentiates NDC-1308 from ALL other Multiple Sclerosis drugs.
NDC-1308: A NOVEL THERAPEUTIC FOR TREATING NEURODEGENERATIVE DISEASE IN THE CNS AND ARDS
With its dual mechanism-of-action, NDC-1308 has the potential to:
- Directly induce remyelination of demyelinated axons within the CNS
- Protect the CNS from demyelination for a prolonged time
NDC-1308 upregulates the expression of the gene for lipoprotein lipase (LPL) within macrophages causing their polarization to the M2, anti-inflammatory, pro-repair state.